Clinical Trials Browser

Phase 2 × Completed × GSK2141795 × Clear all

NCT01941927 2020-02-12

Trametinib With GSK2141795 in BRAF Wild-type Melanoma

Phase 2 Completed

20 enrolled 16 charts

Melanoma

NCT01964924 2019-09-20

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

Phase 2 Completed

37 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms